{
  "generated": "2025-11-06T07:17:28.084207+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/immune/quercetin-infl-inf05/inflammation/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "INFL-INF05_01",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "skin_inflammation",
      "population": "Adults with skin inflammation concerns",
      "adverse_events": "Transient headache",
      "doi": "10.1234/quercetin-infl-inf05-01",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-01",
      "citation": "INFL-INF05_01 (2016); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with skin inflammation concerns; Outcome: skin_inflammation; DOI: 10.1234/quercetin-infl-inf05-01; Adverse Events: Transient headache."
    },
    {
      "study_id": "INFL-INF05_02",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "skin_inflammation",
      "population": "Adults with skin inflammation concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/quercetin-infl-inf05-02",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-02",
      "citation": "INFL-INF05_02 (2017); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with skin inflammation concerns; Outcome: skin_inflammation; DOI: 10.1234/quercetin-infl-inf05-02; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "INFL-INF05_03",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "inflammation_journal",
      "outcome": "skin_inflammation",
      "population": "Adults with skin inflammation concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/quercetin-infl-inf05-03",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-03",
      "citation": "INFL-INF05_03 (2018); Journal: inflammation_journal; Design: randomized controlled trial; Population: Adults with skin inflammation concerns; Outcome: skin_inflammation; DOI: 10.1234/quercetin-infl-inf05-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-infl-inf05-01",
      "study_ids": [
        "INFL-INF05_01"
      ],
      "primary_study_id": "INFL-INF05_01",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-infl-inf05-02",
      "study_ids": [
        "INFL-INF05_02"
      ],
      "primary_study_id": "INFL-INF05_02",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-infl-inf05-03",
      "study_ids": [
        "INFL-INF05_03"
      ],
      "primary_study_id": "INFL-INF05_03",
      "url": "https://doi.org/10.1234/quercetin-infl-inf05-03"
    }
  ],
  "manifest_hash": "sha256:4e977f70da40ca79f8069f6d9168a7a64fb23dd95b8fb0d6b2fdf2af66c480bc"
}
